Oral disease-modifying therapies for multiple sclerosis in the Middle Eastern and North African (MENA) region: an overview

Current Medical Research and Opinion
Dirk DeleuYolande Hanssens

Abstract

The introduction of new disease-modifying therapies (DMTs) for remitting-relapsing multiple sclerosis (RRMS) has considerably transformed the landscape of therapeutic opportunities for this chronic disabling disease. Unlike injectable drugs, oral DMTs promote patient satisfaction and increase therapeutic adherence. This article reviews the salient features about the mode of action, efficacy, safety, and tolerability profile of approved oral DMTs in RRMS, and reviews their place in clinical algorithms in the Middle East and North Africa (MENA) region. A systematic review was conducted using a comprehensive search of MEDLINE, PubMed, Cochrane Database of Systematic Reviews (period January 1, 1995-January 31, 2018). Additional searches of the American Academy of Neurology and European Committee for Treatment and Research in Multiple Sclerosis abstracts from 2012-2017 were performed, in addition to searches of the Food and Drug Administration and European Medicines Agency websites, to obtain relevant safety information on these DMTs. Four oral DMTs: fingolimod, teriflunomide, dimethyl fumarate, and cladribine have been approved by the regulatory agencies. Based on the number needed to treat (NNT), the potential role of these DMTs i...Continue Reading

References

Oct 17, 1992·Lancet·E Beutler
Feb 1, 1997·Clinical Pharmacokinetics·J Liliemark
May 8, 1997·Biochemical and Biophysical Research Communications·M VandermeerenJ Geysen
Dec 17, 2003·The Journal of Investigative Dermatology·Felix TreumerUlrich Mrowietz
Apr 30, 2005·European Neurology·A F AlshubailiY Gerish
Sep 15, 2006·The New England Journal of Medicine·Ludwig KapposUNKNOWN FTY720 D2201 Study Group
Jun 6, 2007·Multiple Sclerosis : Clinical and Laboratory Research·Rachel A Farrell, Gavin Giovannoni
Oct 6, 2007·Annals of Neurology·Veronique E MironJack P Antel
Oct 17, 2008·Multiple Sclerosis : Clinical and Laboratory Research·A GajofattoE Waubant
Jan 30, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·T KopadzeB C Kieseier
May 16, 2009·Journal of Neurology·Katherine TreadawayElliot M Frohman
Sep 2, 2009·Current Neuropharmacology·D Moharregh-KhiabaniM Stangel
Nov 19, 2009·Journal of Neurology·Hans-Peter HartungGiancarlo Comi Giancarlo Comi
Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Jeffrey A CohenUNKNOWN TRANSFORMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Gavin GiovannoniUNKNOWN CLARITY Study Group
Jun 11, 2010·Brain : a Journal of Neurology·Antonio ScalfariGeorge C Ebers
Dec 7, 2010·Biochemical and Biophysical Research Communications·Glyn Dawson, Jingdong Qin
Jan 14, 2011·Multiple Sclerosis : Clinical and Laboratory Research·S CookUNKNOWN CLARITY Study Group
Mar 4, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Malte C Claussen, Thomas Korn
Apr 6, 2011·The International Journal of Neuroscience·Jihad Inshasi, Mona Thakre
Jun 15, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jens IngwersenHans-Peter Hartung
Oct 14, 2011·The New England Journal of Medicine·Paul O'ConnorUNKNOWN TEMSO Trial Group
Dec 14, 2011·Clinical Pharmacokinetics·Olivier J DavidRobert L Schmouder
Jan 18, 2012·Multiple Sclerosis : Clinical and Laboratory Research·G GiovannoniE Waubant
Jul 5, 2012·The Australian and New Zealand Journal of Psychiatry·Alexander I Simpson
Sep 13, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Dirk DeleuFaiza Ibrahim
Sep 21, 2012·The New England Journal of Medicine·Robert J FoxUNKNOWN CONFIRM Study Investigators
Sep 21, 2012·The New England Journal of Medicine·Ralf GoldUNKNOWN DEFINE Study Investigators
May 2, 2013·Journal of Neurology·Jeffrey A CohenGordon Francis
May 21, 2013·Expert Opinion on Drug Metabolism & Toxicology·Michael D WieseCatherine O'Doherty
Sep 13, 2013·Multiple Sclerosis : Clinical and Laboratory Research·R AlroughaniJ Al-Hashel
Oct 16, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Patrick VermerschUNKNOWN TENERE Trial Group
Nov 22, 2013·The Annals of Pharmacotherapy·Jineane V Venci, Mona A Gandhi
Apr 18, 2014·Drugs·Amit Bar-OrHeinz Wiendl
Jun 12, 2014·The Annals of Pharmacotherapy·Rajesh BakshiJan Klatt

❮ Previous
Next ❯

Citations

Jun 9, 2020·Journal of Neurology·Emanuele D'AmicoUNKNOWN ITALIAN-DIME-TERI group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Neurology
Woojun KimHo Jin Kim
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Rachel Hutchins Thomas, Richard A Wakefield
© 2022 Meta ULC. All rights reserved